论文部分内容阅读
[目的] 探讨骨化三醇胶丸对糖尿病肾病(DN)患者尿蛋白水平的影响.[方法] 选取DN患者86例,随机分为两组,每组43例.对照组采用控制血压、血糖及血脂等基础治疗,观察组在上述治疗的基础上口服骨化三醇胶丸,治疗持续3个月.比较两组患者的治疗有效率及患者治疗前后的白蛋白排泄率(uAER)、血肌酐(SCr)和肾小球滤过率(eGFR)及尿蛋白/肌酐比值(UAlb/Cr)变化.[结果] 两组患者治疗后的uAER、SCr及UAlb/Cr水平均较治疗前明显降低(P<0.05),但观察组治疗后降低更明显,其差异均有统计学意义(P<0.05);两组治疗前后eGFR比较差异无统计学意义(P<0.05).与治疗前相比,两组患者治疗后的收缩压(SBP)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)及低密度脂蛋白胆固醇(LDL-C)明显下降(P<0.05),1.25二羟基维生素D3[1,25(OH)2D3] 及高密度脂蛋白胆固醇(HDL-C)较治疗前明显上升(P<0.05);观察组治疗后的FPG、HbA1c明显低于对照组,1,25(OH)2D3显著高于对照组,其差异均有统计学意义(P<0.05).患者治疗后的1,25(OH)2D3水平与临床疗效、治疗后的uAER、UAlb/Cr及血压有显著相关性(P<0.05).观察组有效率为83.72%(36/43),显著高于对照组62.79%(27/43),其差异有统计学意义(X2=4.807,P<0.05).[结论] 骨化三醇胶丸可有效改善DN患者的肾功能,并降低尿蛋白水平,值得临床推广应用.“,”[Objective]To study the influence of calcitriol soft capsules on urine protein of patients with diabetic nephropathy (DN).[Methods]From January 2014 to April 2016, 86 patients with DN were chosen as study objects.All patients were divided into 2 groups: the control group and the study group.The 43 patients in the control group were treated with anti-hypertension/ hyperglycemia/ hyperlipidemia, while the 43 patients in the study group were treated with calcitriol soft capsules for 3 months in addition to anti-hypertension/ hyperglycemia/ hyperlipidemia.The effect rate, SCr, uAER, eGFR and UAlb/Cr were compared between two groups.[Results]After treatment, the uAER, SCr and UAlb/Cr of patients in the two groups decreased significantly (P<0.05), but the levels in the study group showed more dramatic decrease (P0.05).Compared to before treatment, the systolic blood pressure (SBP), fasting blood glucose (FPG), glycosylated hemoglobin (HbA1c) and low density lipoprotein cholesterol (LDL-C) in two groups were significantly decreased (P<0.05), while 1,25(OH)2D3 and high density lipoprotein cholesterol (HDL-C) were significantly higher than those before treatment (P<0.05).After treatment, the levels of FPG and HbA1c were significantly lower in the study group than those in the control group (P<0.05), but the level of 1,25(OH)2D3 was significantly increased (P<0.05).The level of 1,25 (OH)2D3 after treatment was significantly correlated with clinical efficacy, uAER, UAlb / Cr and blood pressure (P<0.05).The effect rate of study group was 83.72%(36/43) compared to that of the control group, which was 62.79%(27/43);the difference had statistical significance (X2=4.807,P<0.05).[Conclusion]Calcitriol soft capsules can help increase the kidney function of patients with DN, as well decrease the urine protein.